MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Alexion Pharmaceuticals Company Profile (NASDAQ:ALXN)

Consensus Ratings for Alexion Pharmaceuticals (NASDAQ:ALXN) (?)
Ratings Breakdown: 7 Hold Rating(s), 14 Buy Rating(s), 1 Strong Buy Rating(s)
Consensus Rating:Buy (Score: 2.73)
Consensus Price Target: $210.82 (51.50% upside)

Current Analysts' Coverage Summary for Alexion Pharmaceuticals (NASDAQ:ALXN)
Show:
DateFirmActionRatingPrice TargetActions
2/8/2016JefferiesReiterated RatingHold$190.00 -> $165.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/6/2016Leerink SwannReiterated RatingOutperform$217.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/5/2016Bank of AmericaReiterated RatingBuy$227.00 -> $204.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/4/2016Stifel NicolausLower Price TargetBuy$245.00 -> $230.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/4/2016JPMorgan Chase & Co.Lower Price Target$225.00 -> $185.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/4/2016Jefferies GroupLower Price TargetHold$190.00 -> $165.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/4/2016Goldman SachsLower Price TargetNeutral$199.00 -> $186.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/4/2016Brean CapitalReiterated RatingBuy$221.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/4/2016Piper JaffrayReiterated RatingOverweight$212.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/4/2016BarclaysLower Price TargetEqual Weight$202.00 -> $175.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/19/2016Credit SuisseInitiated CoverageNeutral$201.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/7/2016BTIG ResearchDowngradeBuy -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/6/2016SunTrustInitiated CoverageBuy$225.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/9/2015OppenheimerReiterated RatingOutperform$228.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/3/2015Cowen and CompanyReiterated RatingOutperform$216.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/28/2015Robert W. BairdReiterated RatingOutperform$221.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/13/2015Raymond JamesReiterated RatingStrong-Buy$225.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/2/2015Morgan StanleyUpgradeEqual Weight -> Overweight$186.00 -> $211.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/4/2015Deutsche BankReiterated RatingBuy$215.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/23/2015Sanford C. BernsteinSet Price TargetBuy$267.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/7/2015Citigroup Inc.Set Price TargetHold$208.00 -> $173.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/7/2015NomuraUpgradeNeutral -> Buy$222.00 -> $246.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/21/2014Ned Davis ResearchUpgradeSell -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 2/9/2014 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha